These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24876206)

  • 1. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011.
    Silberstein EB
    J Nucl Med; 2014 Aug; 55(8):1308-10. PubMed ID: 24876206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB
    J Nucl Med; 1998 Dec; 39(12):2190-2. PubMed ID: 9867168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB; Ryan J
    J Nucl Med; 1996 Jan; 37(1):185-92. PubMed ID: 8543992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016.
    Kennedy-Dixon TG; Gossell-Williams M; Cooper M; Trabelsi M; Vinjamuri S
    J Nucl Med; 2017 Dec; 58(12):2010-2012. PubMed ID: 28522742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full report on a survey of adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan.
    Matsuda H; Uehara T; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M;
    Ann Nucl Med; 2020 Apr; 34(4):299-304. PubMed ID: 31989466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography radiopharmaceutical studies in humans: a guide to regulations for academic researchers.
    Fleming IN; Whelan M; Baxendale R; Gilbert FJ; Matthews PP; Aigbirhio FI
    Nucl Med Commun; 2012 Sep; 33(9):899-906. PubMed ID: 22773151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening radiopharmacy practice in IAEA Member States.
    Duatti A; Bhonsle U
    Semin Nucl Med; 2013 May; 43(3):188-94. PubMed ID: 23561456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear medicine practice in Japan: a report of the sixth nationwide survey in 2007.
    Kuwabara Y; Koizumi K; Ushijima Y; Kinuya S; Kinomura S; Suga K; Takeoka H; Takeda T; Toyama H; Arao Y; Nishiyama Y; Murakami K; Morita K
    Ann Nucl Med; 2009 Feb; 23(2):209-15. PubMed ID: 19225946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control of PET radiopharmaceuticals using HPLC with electrochemical detection.
    Nakao R; Furutuka K; Yamaguchi M; Suzuki K
    Nucl Med Biol; 2006 Apr; 33(3):441-7. PubMed ID: 16631094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A portable database of adverse reactions and drug interactions with radiopharmaceuticals.
    Gómez Perales JL; Martínez AA
    J Nucl Med Technol; 2013 Sep; 41(3):212-5. PubMed ID: 23857419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The 36th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 39th Survey in 2013)].
    Matsuda H; Arano Y; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M
    Kaku Igaku; 2015 Feb; 52(1):1-12. PubMed ID: 26502668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fluorine-18 in radiopharmacy].
    de Beco V; Le Bars D; Scherrmann JM
    Ann Pharm Fr; 2008 Jan; 66(1):60-5. PubMed ID: 18435989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The 34th report on survey of the adverse reaction to radiopharmaceuticals (the 37th Survey in 2011)].
    Matsuda H; Arano Y; Okazawa H; Mizumura S; Yokoyama K; Yoshimura M; ; ;
    Kaku Igaku; 2013 Feb; 50(1):13-25. PubMed ID: 23700820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and separation of ''non-standard'' PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland.
    Hohn A; Zimmermann K; Schaub E; Hirzel W; Schubiger PA; Schibli R
    Q J Nucl Med Mol Imaging; 2008 Jun; 52(2):145-50. PubMed ID: 18174878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The 27th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 30th survey in 2004)].
    Kusakabe K; Okamura T; Kasagi K; Komatani A; Sato Y; Matsuda H; Maruno H; ;
    Kaku Igaku; 2006 Feb; 43(1):23-35. PubMed ID: 16634540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The 30th report on survey of the adverse reaction to radiopharmaceuticals (the 33rd survey in 2007)].
    Matsuda H; Arano Y; Okazawa H; Okamura T; Mizumura S; Yokoyama K; ;
    Kaku Igaku; 2009 Mar; 46(1):29-41. PubMed ID: 19413193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The 29th report on survey of the adverse reaction to radiopharmaceuticals (the 32nd survey in 2006)].
    Kusakabe K; Arano Y; Okamura T; Kasagi K; Komatani A; Matsuda H; Maruno H; ; ;
    Kaku Igaku; 2008 Feb; 45(1):19-35. PubMed ID: 19594097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimising activity and dose with enhanced image quality by radiopharmaceutical administrations.
    Hoeschen C; Mattsson S; Cantone MC; Mikuz M; Lacasta C; Ebel G; Clinthorne N; Giussani A
    Radiat Prot Dosimetry; 2010; 139(1-3):250-3. PubMed ID: 20228050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of adverse reactions to radiopharmaceuticals in Europe.
    Hesslewood SR; Keeling DH
    Eur J Nucl Med; 1997 Sep; 24(9):1179-82. PubMed ID: 9283115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.